It is good time to reduce the shares now, it will pay off in future.
FITB has a good size but an acquisition also makes sense.
Is this the first time you play the market? So, let me tell you a simple fact about stocks. They drop very hard on bad news but recover slowly with good news.
GILD will recover but investors are scared from the market as today but they step in slowly or sell other stocks to gather cash to buy GILD. This process takes some times and that is the reason that GILD does not go up by 10% in one day but it will takes a few days to fully recover.
So, you think you know better than GILD management and their advisers. Send them your resume and also tell us what have you managed with any success in the past so we can see the light. If not then talk-is-cheap.
Not only Horvoni clinical data is superior but also it is a single pill peer day while Viekire requires 4-6 pills with dosing more than once daily.
2- easier compliance
3- much less side effect
4- most patients qualify
Which public are you talking about? ML misled that public who are weak hands and in doubt like yourself. Short sellers took advantage of that public. Now, the reality will come back to them. The weak hands have been manipulated andd GILD will recover as it has been so far by 8% from its low of $86. After all, new investors benefited, shorts benefited, and weak hand who exited at lows lost their money.
ABBV is one of the worst stock with very blink future. ABT investors were worry about HUMIRA in 2013. Eventually, ABT came with a solution to spun off ABBV at low cost while keeping most tangible assets. HUMIRA was the only product that produced huge revenue but it will be gone in a year or so. Poor ABBV investors have to see a huge price drop as soon as the first generic Humira is applied. The ABBV hep c is the last chance to keep some investors but GILD is not a tigger paper. GILD hep c drug are superior and poor ABBV has to come up with something else before its drug becomes obsolete like Vertex INCIVEK.
ML used to manipulate the stocks. After It was acquired by BAC, ML was limited but still it cannot quit its bad habit. ML was the only firm that came with rediculous rating for GILD in favor of its long friend ABBV. However, most analysts ignored BAC/ML to be very wrong. ML is still acting for a purpose other than true facts.
ML has become a broken firm with no respect.
If a doctor is ill informed and he does not educate himself but prescribes a drug based on a sales pitch then he should not be in business. The patients should not trust him and his organization should be banned from practing medicine.
A doctor should do his his patients with best medicine available in a way that cause no side effects or minimum side effect to his patients.
ABT knew this is happening so it spun off ABBV.
As soon as a company apply for generic HUMIRA then ABBV will drop like a rock from sky.
First, you do not need to be a doctor...to know this simple info. After all, who are you that does not know the basic about drugs. At leatst, I have been working in this field for 20 years.
When there is a better drug then less effective drug with multiple side reflect should be banned. If not then patients will stop using it anyway.
INCIVEK from VRTX used to be the number one hep C drug but GILD pushed it out and that exactly will happen to ABBV v pak.
They formed an evil triangle to force patients to a toxic drug for thier greed.
No patient prefer pain and side effect of ABBV v pak drug that may not be effective.
Patients should demand the best drug, the gild HCV drug.